Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Sep 5, 2024

31100_dirs_2024-09-05_504cccd4-c0de-4e54-94ed-fbc16e0f40f6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-09-03

Reporting Person: Wassil Jim (CHIEF OPERATING OFFICER)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-09-03 Common Stock M 10000 $2.42 Acquired 217503 Direct
2024-09-03 Common Stock S 258 $108.0126 Disposed 217245 Direct
2024-09-03 Common Stock S 2072 $110.0794 Disposed 215173 Direct
2024-09-03 Common Stock S 3102 $111.0214 Disposed 212071 Direct
2024-09-03 Common Stock S 2263 $111.8458 Disposed 209808 Direct
2024-09-03 Common Stock S 367 $112.9471 Disposed 209441 Direct
2024-09-03 Common Stock S 389 $114.2538 Disposed 209052 Direct
2024-09-03 Common Stock S 344 $115.1458 Disposed 208708 Direct
2024-09-03 Common Stock S 1195 $116.4249 Disposed 207513 Direct
2024-09-03 Common Stock S 10 $117.025 Disposed 207503 Direct
2024-09-03 Common Stock F 5545 $110.15 Disposed 201958 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-09-03 Stock Option (right to buy) $2.42 M 10000 Disposed 2029-12-16 Common Stock (10000) Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.67 to $108.425. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $109.415 to $110.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $110.43 to $111.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $111.48 to $112.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.57 to $113.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F7: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.84 to $114.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F8: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.97 to $115.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F9: The price reported is a weighted-average price. The shares were sold at prices ranging from $116.02 to $117.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F10: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person.

F11: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.